CCM
ALXN

Cadian Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Cadian Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-245,000
Closed -$34.4M – 42
2017
Q3 		$34.4M Buy
245,000
+70,000
+40% +$9.51M 1.61% 19
2017
Q2 		$21.3M Buy
+175,000
New +$20.4M 1.04% 28

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cadian Capital Management's ALXN Position: Q4 2017 in Review

Cadian Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 245,000 shares — an estimated $34.4M sold.

Cadian Capital Management first reported a position in ALXN in Q2 2017 and held it in 2 quarters. The position peaked at $34.4M in Q3 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Cadian Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cadian Capital Management sold 245,000 Alexion Pharmaceuticals shares in Q4 2017, an estimated $34.4M.
  • Cadian Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Cadian Capital Management's Alexion Pharmaceuticals position peaked at $34.4M in Q3 2017.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Cadian Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.